|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer
Special Category: CTSU trial, NCI Web site featured trial Trial Description Drugs used in chemotherapy such as doxorubicin, cisplatin, paclitaxel, and carboplatin use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating endometrial cancer. This randomized phase III trial is studying two combination chemotherapy regimens to compare how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned (have an equal chance of being placed) to one of two groups. Patients in group one will receive an infusion of doxorubicin and a 1- to 1.5-hour infusion of cisplatin on day 1. They will receive a 3-hour infusion of paclitaxel on day 2 and injections of filgrastim on days 3-12. Patients in group two will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin on day 1. Treatment in both groups may be repeated every 3 weeks for up to seven courses. Quality of life will be assessed periodically. Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Gynecologic Oncology Group
Related Information
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |